Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine
Pancreatic ductal adenocarcinoma (PDAC) represents 90% of pancreatic malignancies. In contrast to many other tumor entities, the prognosis of PDAC has not significantly improved during the past thirty years. Patients are often diagnosed too late, leading to an overall five-year survival rate below 1...
Main Authors: | Pierre-Olivier Frappart, Thomas G. Hofmann |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/10/2750 |
Similar Items
-
Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
by: Natalia Michalak, et al.
Published: (2023-06-01) -
Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
by: Monika Kapszewicz, et al.
Published: (2021-11-01) -
The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment
by: Stavros P. Papadakos, et al.
Published: (2023-02-01) -
Mutant SF3B1 promotes malignancy in PDAC
by: Patrik Simmler, et al.
Published: (2023-10-01) -
Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma
by: Loryn Holokai, et al.
Published: (2020-12-01)